Table 2.

Associations between tumor-infiltrating lymphocytes and patient outcome in Chinese luminal breast cancer patients

Measure	DFS						OS
	Univariate			Multivariate*			Univariate			Multivariate*
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
sTILs (<10%/≥10%)	1.07	0.72, 1.60	0.735	0.83	0.51, 1.36	0.464	0.75	0.32, 1.75	0.503	0.60	0.22, 1.63	0.314
Luminal A	1.56	0.95, 2.56	0.080	1.15	0.61, 2.17	0.658	0.64	0.18, 2.23	0.480	0.61	0.13, 2.82	0.529
Luminal B/HER2-	0.48	0.19, 1.22	0.124	0.37	0.11, 1.25	0.108	0.28	0.03, 2.33	0.238	0.50	0.03, 7.60	0.618
Luminal B/HER2+	0.79	0.30, 2.11	0.639	0.65	0.20, 2.12	0.478	0.43	0.07, 2.58	0.357	0.94	0.13, 6.97	0.955
sCD8 (<5%/≥5%)	0.66	0.32, 1.35	0.254	0.75	0.35, 1.61	0.463	0.89	0.28, 2.85	0.850	1.35	0.39, 4.67	0.638
iCD8 (<1%/≥1%)	0.51	0.26, 0.96	0.042	0.48	0.25, 0.92	0.027	0.33	0.10, 1.03	0.057	0.35	0.11, 1.10	0.073

Abbreviations: DFS, disease-free survival; OS, overall survival; HR, hazard ratio; sTILs, stromal tumor-infiltrating lymphocytes; BC, breast cancer; sCD8, stromal CD8+ T-cells; iCD8, intratumoral CD8+ T-cells.

^*The multivariate model contains the prognostic factors that remained significant in the univariate Cox-regression model after backward elimination including Age, Vascular invasion, Ki-67 labeling index, Tumor size, LN status, pTNM stage, Type of surgery, Herceptin therapy for sTILs with DFS and OS; Tumor size, LN status, pTNM stage for sCD8 and iCD8 with DFS; Tumor size, pTNM stage for sCD8 and iCD8 with OS; significance level of 0.1; An additional table shows this in more detail [see Supplementary Table 2].